Abstract Library

#1388 Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate

Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bergsma H

Authors: Bergsma H, Konijnenberg M, Van der Zwan W, Kam B, Teunissen J,

Keywords: PRRT, Kidneys, Toxicity, Dosimetry,

#900 Renal Effects of Streptozocin: Preliminary Results of the STREPTOTOX Study

Introduction: Based on old studies, Streptozocin (STZ) is known to have some renal toxicity.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Mitry E

Authors: Mitry E, Brixi H, Lecomte T, Lombard-Bohas C, Seitz J,

Keywords: digestive neuroendocrine tumors, streptozotocin, nephrotoxicity, chemotherapy,

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC

Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Mottaghy F,

Keywords: PRRT, 90y-DOTATOC, dosimetry, 111in-octreotide, amino acids,

#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?

Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Baum R,

Keywords: single kidney, non-functional kidney, peptide receptor radionuclide therapy, NET,

#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)

Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Hommann M, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy, NET, nephrotoxicity, long-term follow-up,